which specializes in antibodies for research, has acquired a stake in
peptide-based bio-venture to enter the peptide drug market.
The company announced on the
18th that it acquired 6,667 shares (3.2% stake) of SupadElixir, a leading peptide bio-venture company.
Peptide medicines are the
minimum functional unit of proteins that have to do with controlling function
and the transaction of vital signs. Only very
small amounts of them can treat diseases thanks to their strong active and
The number of clinical trials are on the rapid
rise as the clinical success rate of new drugs is much higher than that of
SupadElixir, founded in 2009,
is a bio-venture company specializing in peptides. It possesses know-how and
technologies to develop peptide drugs and peptide cosmetic candidates.
It currently possesses 40 kinds of
anti-inflammatory, anticancer, anti-allergic and anti-angiogenesis substances as
well as nine patents